MHC-HM416TP | 价格

MHC-HM416TP-100μg / 询价

MHC-HM416TP-500μg / 询价

MHC-HM416TP-500μgx2 / 询价

PE-Labeled Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant PE-Labeled Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. PE-Labeled Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin.
It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRRC peptide [Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&HMTEVVRRC].

波长(Wavelength)

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Supplied as 0.22μm filtered solution in PBS, 0.2% BSA (pH 7.4).

存储(Storage)

Valid for 6 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles and protect from light.

产品数据(Assay Data)
ELISA Data

Immobilized PE-Labeled Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 11.5ng/ml determined by ELISA (QC Test).

背景(Background)

p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.

分子别名(Synonyms)

MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53

文献(References)

(1)Donnellan Z , Bossi G , Harper J , et al. ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing[J]. Journal for ImmunoTherapy of Cancer, 2015, 3(Suppl 2):P299.